Regulatory approval of CPX-351 for secondary AML VJHemOnc – Video Journal of Hematology & HemOnc 2:11 6 years ago 127 Далее Скачать
CPX-351 for secondary AML: pharmacokinetics, administration & impact on treatment VJHemOnc – Video Journal of Hematology & HemOnc 3:48 5 years ago 169 Далее Скачать
CPX-351: Liposomal Cytarabine/Daunorubicin in Secondary AML Targeted Oncology 4:13 5 years ago 264 Далее Скачать
Lifting limits: liposomal delivery of chemotherapy for secondary AML with CPX-351 VJHemOnc – Video Journal of Hematology & HemOnc 2:41 6 years ago 110 Далее Скачать
Outcomes of patients with de-novo vs secondary AML treated with CPX-351 VJHemOnc – Video Journal of Hematology & HemOnc 2:30 2 years ago 205 Далее Скачать
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML? American Society of Hematology 6:26 8 years ago 867 Далее Скачать
Combining venetoclax with CPX-351 for AML VJHemOnc – Video Journal of Hematology & HemOnc 5:03 3 years ago 106 Далее Скачать
The promise of CPX-351 in secondary AML VJHemOnc – Video Journal of Hematology & HemOnc 0:36 4 months ago 66 Далее Скачать
Improved understanding of CPX-351 in AML: impact of HCT & final EAP results VJHemOnc – Video Journal of Hematology & HemOnc 3:07 5 years ago 178 Далее Скачать
Liposomal chemotherapy CPX-351: safety profile VJHemOnc – Video Journal of Hematology & HemOnc 1:04 6 years ago 108 Далее Скачать
Safety and efficacy of CPX-351 in newly diagnosed AML patients under the age of 60 VJHemOnc – Video Journal of Hematology & HemOnc 2:05 2 years ago 129 Далее Скачать
Analyzing the cost-effectiveness of CPX-351 in patients with AML VJHemOnc – Video Journal of Hematology & HemOnc 2:01 2 years ago 78 Далее Скачать
What are the next steps for liposomal chemotherapy delivery and CPX-351? VJHemOnc – Video Journal of Hematology & HemOnc 2:25 6 years ago 113 Далее Скачать
Overview of 4 FDA Approvals in Acute Myeloid Leukemia Targeted Oncology 2:26 6 years ago 296 Далее Скачать
